Friday, 18 December 2020

Mesoblast shares savaged on poor COVID trial results

The stem cell treatment hopeful plunged 41 per cent at the open after revealing its COVID research was unlikely to meet its goals.

from Sydney Morning Herald - Latest News https://ift.tt/37udHRJ
via IFTTT
at
Labels: ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)